X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DR. REDDYS LAB - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DR. REDDYS LAB IPCA LABS/
DR. REDDYS LAB
 
P/E (TTM) x 28.0 27.4 102.0% View Chart
P/BV x 2.1 2.8 75.9% View Chart
Dividend Yield % 0.2 1.0 23.9%  

Financials

 IPCA LABS   DR. REDDYS LAB
EQUITY SHARE DATA
    IPCA LABS
Mar-17
DR. REDDYS LAB
Mar-16
IPCA LABS/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6434,383 14.7%   
Low Rs5032,750 18.3%   
Sales per share (Unadj.) Rs254.4920.1 27.7%  
Earnings per share (Unadj.) Rs16.1126.1 12.7%  
Cash flow per share (Unadj.) Rs29.8183.0 16.3%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.20.6 31.1%  
Book value per share (Unadj.) Rs194.6685.8 28.4%  
Shares outstanding (eoy) m126.20170.61 74.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.33.9 58.1%   
Avg P/E ratio x35.728.3 126.1%  
P/CF ratio (eoy) x19.219.5 98.7%  
Price / Book Value ratio x2.95.2 56.6%  
Dividend payout %6.215.9 39.2%   
Avg Mkt Cap Rs m72,300608,481 11.9%   
No. of employees `00013.321.7 61.4%   
Total wages/salary Rs m6,96031,874 21.8%   
Avg. sales/employee Rs Th2,413.57,244.4 33.3%   
Avg. wages/employee Rs Th523.21,470.9 35.6%   
Avg. net profit/employee Rs Th152.4992.8 15.4%   
INCOME DATA
Net Sales Rs m32,106156,978 20.5%  
Other income Rs m2262,693 8.4%   
Total revenues Rs m32,332159,671 20.2%   
Gross profit Rs m4,44834,587 12.9%  
Depreciation Rs m1,7309,705 17.8%   
Interest Rs m241824 29.2%   
Profit before tax Rs m2,70326,751 10.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6755,237 12.9%   
Profit after tax Rs m2,02821,514 9.4%  
Gross profit margin %13.922.0 62.9%  
Effective tax rate %25.019.6 127.6%   
Net profit margin %6.313.7 46.1%  
BALANCE SHEET DATA
Current assets Rs m17,340118,201 14.7%   
Current liabilities Rs m9,55968,368 14.0%   
Net working cap to sales %24.231.7 76.3%  
Current ratio x1.81.7 104.9%  
Inventory Days Days10060 167.2%  
Debtors Days Days5797 58.7%  
Net fixed assets Rs m20,77972,265 28.8%   
Share capital Rs m252853 29.6%   
"Free" reserves Rs m24,499111,548 22.0%   
Net worth Rs m24,553117,009 21.0%   
Long term debt Rs m3,51710,690 32.9%   
Total assets Rs m39,595200,104 19.8%  
Interest coverage x12.233.5 36.5%   
Debt to equity ratio x0.10.1 156.8%  
Sales to assets ratio x0.80.8 103.4%   
Return on assets %5.711.2 51.3%  
Return on equity %8.318.4 44.9%  
Return on capital %10.521.6 48.6%  
Exports to sales %48.646.3 105.2%   
Imports to sales %14.29.0 159.1%   
Exports (fob) Rs m15,61772,618 21.5%   
Imports (cif) Rs m4,57114,050 32.5%   
Fx inflow Rs m15,61775,405 20.7%   
Fx outflow Rs m5,82827,115 21.5%   
Net fx Rs m9,79048,290 20.3%   
CASH FLOW
From Operations Rs m2,76440,476 6.8%  
From Investments Rs m-1,432-19,421 7.4%  
From Financial Activity Rs m-1,591-17,009 9.4%  
Net Cashflow Rs m-2594,046 -6.4%  

Share Holding

Indian Promoters % 45.9 25.5 180.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 5.4 211.1%  
FIIs % 25.3 35.3 71.7%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.4 15.3 113.7%  
Shareholders   36,892 75,885 48.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  ELDER PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Red; Infosys Tanks as CEO Vishal Sikka Resigns(09:30 am)

Asian indices are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.2%, while the Hang Seng is down 0.7%. The Nikkei 225 is trading lower by 0.9%.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 18, 2017 10:41 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS